Compare Summit Therapeutics Inc (SMMT) vs SanDisk (SNDK) Price & Performance

Summit Therapeutics IncTrade

SanDiskTrade

Price performance (Past 24H)

Key statistics

Summit Therapeutics Inc vs SanDisk — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while SanDisk trades at $1,580.7 (market cap $232.61B). The key difference: SanDisk is far larger — about 17× Summit Therapeutics Inc's market cap, and SanDisk is more actively traded (9,218,054 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and SanDisk for 8 Days on average.

	SMMT	SNDK
Market Cap	$13.71B	$232.61B
Volume	6,173,057	9,218,054
Sector	Health	Technology
52-Week High	$26.38	$2.34K
52-Week Low	$12.43	$116.91
Typical Hold Time	16 Days	8 Days
Enterprise Value	$13.04B	$228.03B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.

SanDisk

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SMMT

No sentiment data available yet.

SNDK

81% Buy19% Sell

Avg holding period · 8 Days

Top news

Latest headlines on both assets

SMMT

AstraZeneca invests $2B in Summit Therapeutics to advance next-gen cancer drug ivonescimab.CNBC · 4 days agoBullish View details →

SNDK

NVIDIA, Micron, and SanDisk poised for strong 2027 gains amid AI chip demand and supply constraints.24/7 Wall Street · 12 hours agoBullish Memory chip stocks SanDisk and Micron rise 3% on tight supply despite broader tech weakness24/7 Wall Street · 2 days agoBullish Wall Street analysts remain bullish on SanDisk despite recent stock drop, with price targets up to $3,000.Finbold · 2 days agoBullish View details →

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

About SanDisk

Sandisk is a semiconductor memory company specializing in NAND flash technology. Its storage products support consumer devices, enterprise systems, and cloud and AI infrastructure.